Page 5 - November 2020 Newsletter - Class Members Edition

setting of Alzheimer’s Disease. This brain criteria. The Settlement Agreement states
imaging, often called “Amyloid PET,” is meant that the identification of a condition – for
to assist clinicians in detecting whether example, through a blood test, genetic
Alzheimer’s Disease is the cause of cognitive test, imaging technique, or otherwise – that

impairment. However, has not yet resulted
a positive amyloid in actual cognitive
PET scan does not There are 370 FAQs in 17 categories. impairment and/or
establish a diagnosis These FAQs contain links to other actual neuromuscular
of Alzheimer’s tools and resource guides posted on impairment
Disease or any other the Settlement Website. The FAQs experienced by
cognitive disorder. page is searchable, so you can quick- the Retired NFL
ly find information you are looking for. Football Player
The PET results and Let us know if you have questions does not qualify as a
Settlement criteria about an FAQ or if there is a topic you Qualifying Diagnosis.
assess different think we should cover in an FAQ. There must be an
things; the amyloid actual manifestation
Frequently Asked Questions PET identifies the of cognitive impairment and/or actual
presence or absence of a pathological
feature in the brain, while the Settlement neuromuscular impairment.
The FAQs (Frequently Asked Questions) section of the Settlement Website documents criteria require an assessment of the NFL Auxiliary tests for Parkinson’s disease may
the rules and processes we follow in the Program. We add new FAQs and update existing Player’s clinical condition. Therefore, a PET include biomarker tests such as an alpha-
FAQs as changes to our rules/processes occur. When we feel you need to know about scan showing amyloid neuritic plaque in the synuclein skin biopsy or Ioflupane (123I)
a FAQ change immediately, we will notify you with an email alert. In our quarterly Status brain may support an Alzheimer’s Disease dopamine transporter (DaT) single photon

Reports we file with the Court, we describe all new FAQs and changes to existing FAQs. diagnosis but does not establish an actual emission computed tomography (SPECT)
manifestation of cognitive impairment, which scan (DaT scan), or neurophysiological
We updated FAQs 117 and 119 and created imaging technique (e.g., quantitative MRI), is required under the Settlement criteria. studies of tremor. Although these auxiliary
new FAQs 118 and 120 to clarify newer or otherwise – that has not yet resulted in As a general matter with respect to the tests alone are not sufficient to fulfill the
and auxiliary testing for Alzheimer’s and actual cognitive impairment and/or actual Qualifying Diagnoses, Class Counsel and Settlement criteria, their potential, non-
Parkinson’s Disease, and how those tests neuromuscular impairment experienced Counsel for the NFL Parties will address mandatory use may influence the overall

interact with the Settlement criteria: by the Retired NFL Football Player does possible advances in science to effectuate certainty of a diagnosis of Parkinson’s
not qualify as a Qualifying Diagnosis. There Disease. Biomarker tests may assist the
118. Is a biomarker test (such as an must be an actual manifestation of cognitive the mutual intent that Players manifest diagnosing physician to determine whether
amyloid PET, spinal fluid test) enough impairment and/or actual neuromuscular actual cognitive impairment and/or actual a Retired Player’s signs or symptoms are
to establish my Qualifying Diagnosis of impairment. neuromuscular impairment. related to Parkinson’s disease.

Alzheimer’s Disease? 120. Are auxiliary tests, including
For example, a positron emission As a general matter with respect to the
No, a biomarker test, by itself, is not sufficient tomography (“PET”) scan is a nuclear biomarker tests, enough to establish Qualifying Diagnoses, Class Counsel and
to establish a Qualifying Diagnosis of medicine imaging test that uses a radioactive my Qualifying Diagnosis of Parkinson’s Counsel for the NFL Parties will address
Alzheimer’s Disease under the Settlement molecule to show any abnormalities in bodily Disease? possible advances in science to effectuate
criteria. The Settlement Agreement states function. Florbetapir, Flutemetamol, and No, auxiliary tests alone are not sufficient the mutual intent that Players manifest

that the identification of a condition – for Florbetapen, have been approved by the to establish a Qualifying Diagnosis of actual cognitive impairment and/or actual
example, through a blood test, genetic test, FDA for PET imaging of β-amyloid in the Parkinson’s Disease under the Settlement neuromuscular impairment.

4 INSIGHTS Class Members Edition December 2020 December 2020 INSIGHTS Class Members Edition 5